Indications
Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.
Composition
- Active substance
- vadadustat
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vafseo
- Active substance
- vadadustat
- Therapeutic area
- Renal Insufficiency, Chronic, Anemia
- Marketing authorisation holder
- Medice Arzneimittel Pütter GmbH & Co. KG
- Status
- Authorised
- EU authorisation
- 24 Apr 2023
- EMA product number
- EMEA/H/C/005131
EMA designations
- Orphan medicine
- No
- Conditional approval
- No
- Biosimilar
- No
- Generic
- No
- Accelerated assessment
- No
- Additional monitoring
- Yes
- Patient safety information
- No